Medical research explores new methods to reduce fat and activate brown adipose tissue

Recent medical research has highlighted new approaches to managing body fat and its metabolic benefits. Clinical trials for an injection called CBL-514 have shown promise in reducing both subcutaneous and visceral fat. In a follow-up analysis of 41 participants, those receiving the injection for up to 12 weeks saw an average reduction of 12.01 percent in visceral fat, whereas the placebo group saw an average increase of 5.68 percent.

Unlike traditional weight-loss methods, CBL-514 works by encouraging the death of fat cells. Researchers suggest this could potentially make it harder to regain weight after treatment, though further human studies are required. Early results also indicate that reducing visceral fat may improve blood pressure and cholesterol levels.

Separately, researchers at Rockefeller University have identified a link between the blood pressure medication losartan and the presence of brown adipose tissue. Brown fat is specialized tissue that burns calories to generate heat and regulate body temperature. Using artificial intelligence to analyze medical records from over 100,000 participants, the study suggests that certain medications could be repurposed to activate this beneficial type of fat to improve physical and mental health.